We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Low Phenylalanine Diet for Mothers With Phenylketonuria (PKU)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00065299
Recruitment Status : Completed
First Posted : July 22, 2003
Last Update Posted : June 24, 2005
Information provided by:
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Brief Summary:
Phenylketonuria (PKU) is a rare genetic condition. If not treated, PKU can cause severe mental retardation. Women with PKU are advised to eat a special diet when pregnant to prevent mental retardation in their children. This study will evaluate the effects of that diet on the children of mothers with PKU.

Condition or disease Intervention/treatment Phase
Phenylketonuria Behavioral: Restricted phenylalanine diet Not Applicable

Detailed Description:

PKU is an autosomal recessive trait caused by the absence of phenylalanine hydroxylase. Phenylalanine hydroxylase is an enzyme involved in the metabolism of phenylalanine (Phe). When phenylalanine hydroxylase is absent or defective, Phe levels rise and toxic Phe metabolites accumulate, causing central nervous system injury. PKU is a treatable disease. Affected individuals must adhere to a diet low in Phe during childhood. Women with PKU should also adhere to a low Phe diet before and during pregnancy to avoid fetal damage. The offspring of women with untreated maternal hyperphenylalaninemia (HPA) usually exhibit mental retardation, microcephaly, growth retardation, and other congenital anomalies. This study will examine the effect of a restricted Phe diet on reproductive outcome in women with maternal HPA.

Participants in this study will be women with HPA whose blood Phe values are persistently greater than 4 mg/dl. Those women with blood Phe values consistently greater than 8 mg/dl will be placed on a Phe restricted diet to maintain plasma Phe concentrations between 2 and 8 mg/dl. This level of control is practical and achievable. Due to a gradient of increasing Phe level from mother to fetus, levels in the latter would vary from 3.5 to 12 mg/dl; these levels are usually associated with normal outcomes. Women will be monitored throughout their pregnancy on obstetric, biochemical, and nutritional parameters. Women on the Phe restricted diet will be given enough Phe-limited protein, calories, vitamins, and minerals to maintain adequate nutritional status. Folate supplementation will be provided. If indicated clinically, tyrosine (Tyr) and supplemental trace metals will be prescribed.

A matching control sample of women and their offspring will be developed in collaboration with associated coordinating and collaborating centers. The offspring of both groups of mothers will be followed as long as the project permits. Those offspring born to mothers admitted to the project during the first 2 to 3 years of the study will be assessed on their intellectual ability and physical health, as well as academic achievement in school. Those admitted during the last 3 to 4 years of the study will be assessed on their intellectual ability and physical health, recognizing that limited data will be available for these offspring.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 572 participants
Allocation: Non-Randomized
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Effects of Maternal Phenylketonuria (PKU) on Pregnancy Outcome
Study Start Date : May 1984
Study Completion Date : April 2000

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   0 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria

  • Live in community setting
  • Become pregnant or give birth during the term of the investigation
  • Identified early in pregnancy
  • Dietary therapy instituted prior to conception whenever possible
  • Diagnosis of PKU based on results of Phe challenge, or clear diagnostic evidence in medical record
  • Blood Phe > 4 mg/dl
  • Intellectually able to understand and comply with the requirements of the Phe restricted diet, understand an informed consent, and adequately communicate with clinic personnel
  • IQ > 70

Inclusion Criteria for Controls

  • Heterozygous sisters to HPA women
  • Matched control from maternity facility; pregnancy and offspring from a non-PKU female and a PKU male

Exclusion Criteria

  • Women with evidence of pterin defect

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00065299

Layout table for location information
United States, California
University of Southern California School of Medicine
Los Angeles, California, United States, 90027
United States, Illinois
University of Illinois at Chicago
Chicago, Illinois, United States
United States, Texas
University of Texas Medical Branch at Galveston
Galveston, Texas, United States
Sponsors and Collaborators
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Layout table for investigator information
Principal Investigator: Richard Koch, M.D. University of Southern California
Principal Investigator: Reuben Matalon, M.D. University of Illinois at Chicago
Principal Investigator: Bobbye M. Rouse, M.D. University of Texas at Galveston
Layout table for additonal information
ClinicalTrials.gov Identifier: NCT00065299    
Other Study ID Numbers: NICHD-PKU
First Posted: July 22, 2003    Key Record Dates
Last Update Posted: June 24, 2005
Last Verified: May 2000
Keywords provided by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD):
Maternal PKU
Pregnancy outcome
Phenylalanine restricted diet
Tyrosine supplementation
Maternal hyperphenylalanemia during pregnancy
Additional relevant MeSH terms:
Layout table for MeSH terms
Brain Diseases, Metabolic, Inborn
Brain Diseases, Metabolic
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Amino Acid Metabolism, Inborn Errors
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Metabolic Diseases